New Drugs and Safety
Author:
Open Access
- 26 November 2012
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 172 (21) , 1680-1681
Abstract
Monitoring the safety of drugs is increasingly recognized as a major issue in light of recent experience with products such as rofecoxib and rosiglitazone. Previous work found that the probability of new drugs either acquiring a black box safety warning or being withdrawn for safety reasons was 20% over a 25-year period1 and that oncology drugs that were granted a priority review were more likely to be subject to labeling changes than were drugs with a standard review.2Keywords
This publication has 2 references indexed in Scilit:
- Examination of the Relationship Between Oncology Drug Labeling Revision Frequency and FDA Product CategorizationAmerican Journal of Public Health, 2009
- Timing of New Black Box Warnings and Withdrawals for Prescription MedicationsJAMA, 2002